Q1 FY27 results - Revenue jumps 580% YoY but profit dips

Revenue growth above 20%EBITDA margin compressionResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.4%Reaction day

₹0.41

prior close

₹0.42

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%+2.4% vs market

Pharmaceuticals peers, median of 166sector-0.4%+2.8% vs sector

On the reaction day the stock moved 2.4 pts more than Nifty Microcap 250 and 2.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

-2.4

15m

-2.4

30m

-2.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.4+0.1+2.4-0.4+2.8

Next day

+2.4+0.2+2.2-0.5+2.9

+2.4+0.6+1.9-0.6+3.0

-2.4-0.0-2.4-1.3-1.1

+0.0+0.5-0.5-0.9+0.9

-4.9+0.8-5.6-0.4-4.5

+0.0+0.6-0.6-0.9+0.9

15d

-2.4+1.3-3.7+0.0-2.5

-7.3-1.4-6.0-0.1-7.2

-12.2-0.6-11.6-2.6-9.5

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q1 FY27 revenue from operations rose to Rs 3101.15 lacs vs Rs 455.62 lacs in Q1 FY26, about 580% growth. However, profit after tax fell to Rs 12.30 lacs from Rs 21.51 lacs YoY, as costs scaled faster than revenue. FY26 full year showed a loss of Rs 628.72 lacs on revenue of Rs 14175.23 lacs. Auditor issued a clean limited review report.

Likely market impact

Strong topline growth but weak profit conversion signals margin pressure for shareholders.